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  Investigation was carried out in adult New Zealand white 
rabbits to study the influence of curcumin pre-treatment 
on  pharmacokinetic  disposition  of  norfloxacin  following 
single  oral  administration.  Sixteen  rabbits  were  divided 
into  two  groups  of  eight  each  consisting  of  either  sex. 
Animals  in  group-I  were  administered  norfloxacin  (100 
mg/kg body weight p.o), while animals in group-II received 
similar  dose  of  norfloxacin  after  pre-treatment  with 
curcumin  (60  mg/kg  body  weight  per  day,  3  days,  p.o). 
Blood samples were drawn from the marginal ear vein into 
heparin-coated vials at 0 (zero time), 5, 10, 15, 30 min and 
1, 2, 4, 6, 12 and 24 h post-treatment. Plasma norfloxacin 
concentrations  were  determined  by  high  performance 
liquid  chromatography.  The  plasma  concentration-time 
profile of norfloxacin was adequately described by a one- 
compartment  open  model.  The  pharmacokinetic  data 
revealed that curcumin-treated animals had significantly 
(p ≤ 0.05) higher area under the plasma concentration- 
time  curve  and  area  under  the  first  moment  of  plasma 
drug concentration-time curve. Prior treatment of curcumin 
significantly (p ≤ 0.05) increased elimination half-life and 
volume of distribution of norfloxacin. Further treatment 
with curcumin reduced loading and maintenance doses by 
26% and 24% respectively.
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Introduction 
Norfloxacin is a member of the fluoroquinolone group of 
antimicrobial agents. It has a wide spectrum of activity, 
excellent tissue penetration and is rapidly bactericidal at 
low concentrations. Norfloxacin has a minimum inhibitory 
concentration (MIC90) of 0.06, 0.12, 0.25 and 0.5 mg/mL 
for Haemophilus influenzae, Escherichia coli, Enterobacter 
spp. and Klebsiella spp., respectively [2]. This antibiotic 
shows promise as an antimicrobial agent for bacterial 
diseases of the respiratory, genito-urinary and gastro- 
intestinal tracts [22]. Encouraging results have been 
observed following the therapeutic use of norfloxacin in 
dogs suffering from hemorrhagic gastroenteritis caused by 
E. coli, Salmonella spp., and Shigella spp. [3], and norfloxacin 
has been successfully employed to treat genital tract 
infections caused by Pseudomonas aeruginosa in bulls 
[10]. The absolute bioavailability of norfloxacin in humans 
and in laboratory animals is reported to be 40% [15], while 
in most domestic species the per-os bioavailability varies 
between 30∼40% [11]. 
Turmeric (Curcuma longa) is a medicinal plant extensively 
used in Ayurveda, Unani and Siddha medicine as a home 
remedy for various diseases. Curcumin, which is the active 
component of Curcuma longa, improves the per-os 
bioavailability of the immunosuppressive agent mylophenolic 
acid by inhibiting non-specific drug metabolizing enzymes 
[4]. Similarly, curcumin suppresses drug metabolizing 
enzymes (CYP3A4) in the liver [23] as well as inducing 
changes in the drug transporter P-glycoprotein, hence 
increasing the maximum absorption concentration (Cmax) 
and area under the plasma concentration-time curve 
(AUC) of celiprolol and midazolam in rats [24]. With this 
background, the present study was undertaken to evaluate 
the influence of curcumin pre-treatment on the disposition 
kinetics of norfloxacin and to assess its impact on dosage 
regimen in rabbits.
Materials and Methods
The study was conducted in New Zealand white rabbits 
weighing 1.65 ± 0.22 kg, divided into two groups with 
eight rabbits in each group. The rabbits were acclimatized 
for three weeks to laboratory conditions before initiating 294    B. H. Pavithra et al.
Table 1. Comparison of mean plasma levels of norfloxacin 
(mg/mL) at different time intervals following oral administration
in control (Group-I) and curcumin treated (Group-II) rabbits
Time (h) Group-I Group-II
0.08
0.16
0.25
0.50
1.00
2.00
4.00
6.00
8.00
12.00
24.00
0.37 ± 0.05
0.46 ± 0.04
2.23 ± 0.08
1.50 ± 0.25
0.62 ± 0.01
0.48 ± 0.03
0.41 ± 0.01
0.37 ± 0.01
0.17 ± 0.04
0.01 ± 0.001
ND
0.50 ± 0.25*
2.87 ± 0.17*
1.19 ± 0.01*
1.08 ± 0.03
0.84 ± 0.01*
0.59 ± 0.01*
0.32 ± 0.03
0.21 ± 0.06
0.13 ± 0.01
0.09 ± 0.01*
0.07 ± 0.02
*p ≤ 0.05, ND = Not detected. Data are presented as mean ± SE.
the experiment. They were housed in individual cages and 
fed with antibiotic free diet. Feed and water were provided 
ad libitum. Feed was withheld for at least 6∼8 h before and 
until 4 h after drug administration. Necessary approval 
from the Institutional Animal Ethics Committee was 
obtained to carry out the investigation. 
Norfloxacin (Aravind Pharma, India) was dissolved in 
0.1 N HCl to obtain a 3.33% solution (50 mg of norfloxacin 
in 1.5 mL 0.1 N HCl). The required amount of curcumin 
(Sigma-Aldrich, USA) was dissolved in a mixture of 
distilled water and Tween-20 at a 2 : 1 ratio restricting the 
total volume to 4∼5 mL. Group-I rabbits (control) received 
norfloxacin at the rate of 100 mg/kg body weight as a single 
oral dose. The rabbits in group-II were administered a 
similar dose of norfloxacin after pre-treatment with 
curcumin (60 mg/kg body weight; p.o) for three days at an 
interval of 24 h. Blood samples (1.0∼1.5 mL) were aseptically 
drawn from the marginal ear vein into heparin-coated tubes 
(Hi-Media, India) immediately before (0) at 5, 10, 15 and 
30 min, and 1, 2, 4, 6, 8, 12 and 24 h after the administration 
of norfloxacin. Plasma samples were obtained by 
centrifugation of each blood sample (1,250 ×g, 10 min) and 
were stored at 򰠏20
oC (for not more than 24 h) until being 
assayed. 
Plasma norfloxacin concentrations were determined 
using high performance liquid chromatography (HPLC; 
Shimadzu, Japan). Dilutions of norfloxacin (E. Merck, 
India) ranging from 0.01∼4 mg/mL were carried out with the 
mobile phase to obtain a standard curve. The HPLC system 
consisted of double pump (LC-20AT), rheodyne manual 
injector with 20 μL loop, dual wavelength ultraviolet 
detector (SPD-20A) and LC Solution software for data 
analysis. Chromatography was carried out using a reverse 
phase C18 column (250 × 4.5 mm, particle size 5 ± 0.3 μm, 
pore diameter 100 ± 10 A
o; Phenomenax, USA) as a 
stationary phase. The mobile phase consisted of 0.1% v/v 
orthophosphoric acid (pH adjusted to 2.0) and acetonitrile 
mixed at a v/v ratio of 850 : 150. Chromatography was 
carried out at a flow rate of 1 mL/min at room temperature 
and the absorbance of norfloxacin at 275 nm was 
measured. The cleaned-up plasma samples [16] were 
analyzed for 8 min; there were no interfering peaks in the 
chromatogram at the retention time (Rt = 4.90 ± 0.14 min) 
of norfloxacin. The quantification limit was 0.015 μg/mL 
and the standard curve was linear in the range 0.015∼4 
μg/mL with a R
2 value of 0.999. Extraction recovery was 
determined to be 94.17% by comparing peak areas 
obtained for plasma-based standards and those obtained 
for mobile phase-based standards. The intra- and inter-day 
assay coefficients of variations were ＜ 8.0%.
The plasma concentration-time profile of norfloxacin of 
each experimental animal was used to determine its 
pharmacokinetics. The pharmacokinetic data of norfloxacin 
was analyzed using the ‘method of least square’ and 
‘method of residual yields’ [8]. The compartmental analysis 
of the data was undertaken using the mono-exponential 
equation: 
C
t
p = Be
򰠏βt 򰠏 Ae
򰠏Kat
where, C
t
p = plasma drug concentration, B is the zero-time 
intercept of regression line of elimination phase, A is the 
zero-time plasma drug concentration intercept of regression 
line of absorption phase, Ka is the absorption rate constant, 
β is the overall elimination rate constant, t is the time and 
e is the natural logarithm base.
The total AUC and area under the first moment of plasma 
drug concentration-time curve (AUMC) were calculated 
as described previously [18]. The volume of distribution 
(Vd(area)) and clearance from the body (ClB) were calculated 
as previously described [8] for a non-vascular route of 
administration.
The loading and maintenance dosage schedules were 
selected to maintain a MIC of 0.1, 0.5 and 1.0 μg/mL in 
plasma [12].
The difference between the means of the two treatments 
was determined by student’s t-test [21] and the data were 
analyzed using GraphPad Instant software (GraphPad 
Software, USA).
Results
The mean plasma concentration of norfloxacin was 
significantly (p ≤ 0.05) higher in curcumin pre-treated 
rabbits, although such effect was not observed during the 
entire period of absorption phase (Table 1, Fig. 1). The 
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Fig. 1. Semilogarithmic plot of plasma concentration-time 
profile of norfloxacin in control (Group-I) and curcumin treated 
(Group-II) rabbits following single oral dose administration.
Table 2. Comparative pharmacokinetics of orally administered 
norfloxacin (100 mg/kg body weight) in control (Group-I) and 
curcumin treated (Group-II) rabbits
Parameter Unit Group-I Group-II
Ka
A
β
B
t½Ka
t½β
AUC
AUMC
MRT
Vd(area)
ClB
td
/h
μg/mL
/h
μg/mL
/h
/h
μg/mL/h
μg/mL/h
2
H
L/kg/h
L/kg/h
H
1.84 ± 0.03
1.95 ± 0.14
0.278 ± 0.01
1.04 ± 0.01
0.35 ± 0.01
2.49 ± 0.13
2.67 ± 0.42
13.40 ± 1.62
5.01 ± 0.19
5.69 ± 0.28
1.49 ± 0.11
27.72 ± 6.22
2.59 ± 0.62*
1.85 ± 1.15
0.231 ± 0.03*
1.11 ± 0.02
0.27 ± 0.06*
2.96 ± 0.34*
4.06 ± 1.24*
22.64 ± 6.34*
5.60 ± 0.15*
7.45 ± 1.70*
1.58 ± 0.03
29.58 ± 3.84*
*p ≤ 0.05. ka: absorption rate constant, A: zero time plasma drug 
concentration intercept of regression line of absorption phase, β: 
overall elimination rate constant, B: zero time intercept of regression
of elimination phase, t½Ka: absorption half-life, t½β: elimination 
half-life, AUC: area under the plasma concentration-time curve, 
AUMC: area under first moment of plasma drug concentration-time
curve, MRT: mean residence time, Vd(area): apparent volume of 
distribution, ClB: total body clearance of drug, td: total duration of 
pharmacological effect. Data are presented as mean ±SE.
Table 3. Dosage regimen of norfloxacin, calculated on the basis of pharmacokinetics values of obtained following oral administration
of curcumin treated (Group-II) and control (Group-I) rabbits at various dosage intervals for microorganisms of different susceptibilities
Susceptibility of 
microorganisms 
(MIC)*
Dosage interval
Group-I Group-II
6 h 8 h 12 h 6 h 8 h 12 h
0.1
0.5
1.0
3.01
† (2.45)
‡
15.08 (12.23)
30.16 (24.47)
5.25 (4.69)
26.29 (23.45)
52.59 (46.90)
15.99 (15.42)
79.96 (77.12)
159.92 (77.11)
2.97 (2.23)
14.89 (11.20)
29.79 (22.34)
4.73 (3.98)
23.64 (19.92)
47.29 (39.84)
11.91 (11.17)
59.56 (55.84)
119.13 (111.68)
*Values given are expressed as μg/mL. 
†Values given are expressed as mg/kg body weight. 
‡Values given are loading doses and the values in
parenthesis are maintenance doses.
curcumin-treated rabbits, while it was detected up to 12 h 
in the untreated control group (Table 1). The absorption 
rate constant and absorption half-life revealed a significant 
(p  ≤ 0.05) change (Table 2). Prior administration of 
curcumin modified the kinetic profile of norfloxacin as 
evidenced by the higher AUC, AUMC and mean resident 
time. Prior administration of curcumin significantly (p ≤ 
0.05) reduced the elimination rate constant (β) and 
consequently increased the half-life of norfloxacin. 
Similarly, there was a significant increase in Vd(area) of 
norfloxacin in curcumin-treated rabbits when compared to 
untreated controls (Table 2). Prior treatment with curcumin 
reduced both loading and maintenance doses up to 26.0% 
and 24.0%, respectively, at different norfloxacin MICs 
(Table 3).
Discussion
Norfloxacin has antimicrobial activity against a wide 
range of bacteria and is being effectively used to treat 
respiratory, urinary and gastro-intestinal tract infections in 
man and animals. Pharmacokinetic studies on norfloxacin 
in rabbits are limited [14,19]. The absorption of norfloxacin 
from gastrointestinal tract is limited [5,9]. Curcumin, a 
flavonoid isolated from Curcuma longa, improves the 
therapeutic concentrations of co-administered drugs [4,24]. 
With this background, the present study was undertaken to 
examine the influence of curcumin on the disposition 
profile of norfloxacin in rabbits after oral administration.
The disposition of norfloxacin after a single oral dose 296    B. H. Pavithra et al.
(100 mg/kg body weight) was examined in rabbits with or 
without prior exposure to curcumin. A similar dose (per os) 
has been used to describe plasma and tissue concentration 
of norfloxacin in rabbits [19]. The observed plasma 
concentration-time profile of norfloxacin was best described 
by the one compartment open model. The plasma levels of 
norfloxacin (group-I) at different time intervals were 
comparable to previous studies in rabbits receiving a similar 
dose [19], however, the plasma half-life was relatively short 
[14]. The increased plasma levels of norfloxacin observed 
in the present study (group-II) may be due to the by-pass of 
glucuronidation process in the intestine since curcumin 
was reported to suppress UDP-glucuronyltransferase levels 
in intestine and hepatic tissue [4]. Furthermore, the ability 
of curcumin to suppress CYP3A4 drug metabolizing enzymes 
[23] might have delayed the excretion of norfloxacin. It is 
more likely that the increased absorption observed in the 
present study may have been due to the ability of curcumin 
to influence drug transporter protein (P-gp) in the intestine, 
as occurs with celiprolol [24]. Similarly, curcumin and 
gingerol (from ginger) were observed to inhibit P-gp 
mediated 
3H-digoxin transport in L-MDR 1 and caco-2 
cells  in vitro [23]. Furthermore, the modification of 
physiological activity in the gastrointestinal tract by 
curcumin [3,17] in the group-II rabbits might have 
contributed to the improved absorption of norfloxacin. 
Norfloxacin undergoes extensive metabolism in the liver 
involving both Phase-I and Phase-II [1]. The significantly 
higher values of AUC, AUMC and mean residence time 
(MRT) observed in the present study might be attributable 
to the enhanced systemic availability of norfloxacin 
consequent to inhibition of enzymes mostly concerned 
with the hepatic metabolism of norfloxacin. Furthermore, 
in contrast to the fact that curcumin can induce hepatic 
glucuronyltransferase, its suppression at a higher dose 
cannot be ruled out. It is noteworthy that curcumin is itself 
metabolized through hepatocytes as glucuronides of 
tetrahydrocurcumin [13] and, therefore, the metabolism of 
norfloxacin may be delayed due to competition between 
two substrates.
The higher plasma elimination half life (t1/2β) of 2.96 ± 
0.34 h in the curcumin-treated group when compared to the 
control group could be due to prolonged persistence of the 
drug in the body due to inhibition of one or more enzyme(s) 
concerned with metabolism of norfloxacin. A significant 
amount of norfloxacin was excreted unchanged via renal 
mechanisms [15]. Therefore, it can be hypothesized that 
curcumin might have delayed the excretory mechanism of 
norfloxacin, since P-gp protein also exists in the proximal 
convoluted tubules. 
From a practical point of view, a dosage regimen of 80 
and 77 mg/kg of norfloxacin alone or 60 and 55 mg/kg of 
norfloxacin after curcumin pre-treatment as the loading 
and maintenance dose, respectively, at a 12 h interval 
adequately maintains optimal therapeutic concentration of 
0.5 μg/mL plasma against resistant pathogens infecting 
rabbits. The reduction in the loading and maintenance 
doses indicates that prior administration of curcumin is of 
economic significance as well as being capable of reducing 
side effects, as a lesser amount of drug would be required. 
The bioenhancer nature of curcumin is comparable to 
piperine [20], an alkaloid obtained from Piper longum. 
Thus, bioenhancer properties of curcumin can be clinically 
exploited after appropriate dose titration studies. 
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